1. Torre, LA, Bray, F, Siegel, RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87–108.
Google Scholar | Crossref | Medline | ISI2. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology . Rectal cancer, version 1, 2020, http://www.nccn.org
Google Scholar3. De Felice, F, Benevento, I, Magnante, AL, et al. Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis: oxaliplatin in neoadjuvant treatment for rectal cancer. BMC Cancer 2017; 17: 325.
Google Scholar | Crossref | Medline4. Aria, M, Cuccurullo, C. Bibliometrix: an R-tool for comprehensive science mapping analysis. J Informetrics 2017; 11: 959–975.
Google Scholar | Crossref5. Sauer, R, Becker, H, Hohenberger, W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731–1740.
Google Scholar | Crossref | Medline | ISI6. Sauer, R, Liersch, T, Merkel, S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012; 30: 1926–1933.
Google Scholar | Crossref | Medline | ISI7. Maas, M, Nelemans, PJ, Valentini, V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010; 11: 835–844.
Google Scholar | Crossref | Medline | ISI8. Roh, MS, Colangelo, LH, O’Connell, MJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009; 27: 5124–5130.
Google Scholar | Crossref | Medline9. Gérard, JP, Azria, D, Gourgou-Bourgade, S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010; 28: 1638–1644.
Google Scholar | Crossref | Medline10. Aschele, C, Cionini, L, Lonardi, S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011; 29: 2773–2780.
Google Scholar | Crossref | Medline | ISI11. Rödel, C, Liersch, T, Becker, H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012; 13: 679–687.
Google Scholar | Crossref | Medline12. Willett, CG, Duda, DG, di Tomaso, E, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009; 27: 3020–3026.
Google Scholar | Crossref | Medline | ISI13. Dzik-Jurasz, A, Domenig, C, George, M, et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 2002; 360: 307–308.
Google Scholar | Crossref | Medline | ISI14. Jeong, SY, Park, JW, Nam, BH, et al. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. Lancet Oncol 2014; 15: 767–774.
Google Scholar | Crossref | Medline15. Leroy, J, Jamali, F, Forbes, L, et al. Laparoscopic total mesorectal excision (TME) for rectal cancer surgery: long-term outcomes. Surg Endosc 2004; 18: 281–289.
Google Scholar | Crossref | Medline | ISI16. Patel, UB, Taylor, F, Blomqvist, L, et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol 2011; 29: 3753–3760.
Google Scholar | Crossref | Medline17. Capirci, C, Valentini, V, Cionini, L, et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 2008; 72: 99–107.
Google Scholar | Crossref | Medline | ISI18. Guillem, JG, Chessin, DB, Cohen, AM, et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg 2005; 241: 829–836.
Google Scholar | Crossref | Medline19. Beets-Tan, RG, Beets, GL. Rectal cancer: review with emphasis on MR imaging. Radiology 2004; 232: 335–346.
Google Scholar | Crossref | Medline20. Braendengen, M, Tveit, KM, Berglund, A, et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 2008; 26: 3687–3694.
Google Scholar | Crossref | Medline | ISI21. Valentini, V, Coco, C, Picciocchi, A, et al. Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys 2002; 53: 664–674.
Google Scholar | Crossref | Medline22. Rödel, C, Graeven, U, Fietkau, R, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2015; 16: 979–989.
Google Scholar | Crossref | Medline | ISI23. Theodoropoulos, G, Wise, WE, Padmanabhan, A, et al. T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum 2002; 45: 895–903.
Google Scholar | Crossref | Medline | ISI24. Ghadimi, BM, Grade, M, Difilippantonio, MJ, et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 2005; 23: 1826–1838.
Google Scholar | Crossref | Medline | ISI25. Wang, K, Feng, C, Li, M, et al. A bibliometric analysis of 23,492 publications on rectal cancer by machine learning: basic medical research is needed. Therap Adv Gastroenterol 2020; 13: 1756284820934594.
Google Scholar | SAGE Journals | ISI26. Musio, D, De Felice, F, Bulzonetti, N, et al. Neoadjuvant-intensified treatment for rectal cancer: time to change? World J Gastroenterol 2013; 19: 3052–3061.
Google Scholar | Crossref | Medline27. Fokas, E, Allgäuer, M, Polat, B, et al. Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. J Clin Oncol 2019; 37: 3212–3222.
Google Scholar | Crossref | Medline28. De Felice, F, Musio, D, Tombolini, V, et al. Commentary on: ‘Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12’. Int J Colorectal Dis 2019; 34: 1617–1618.
Google Scholar | Crossref | Medline29. Bahadoer, RR, Dijkstra, EA, van Etten, B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22: 29–42.
Google Scholar | Crossref | Medline30. Conroy, T, Bosset, JF, Etienne, PL, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22: 702–715.
Google Scholar | Crossref | Medline